US2019300614A1PendingUtilityA1

Antibodies against human csf-1r and uses thereof

71
Assignee: HOFFMANN LA ROCHEPriority: Dec 10, 2009Filed: Mar 25, 2019Published: Oct 3, 2019
Est. expiryDec 10, 2029(~3.4 yrs left)· nominal 20-yr term from priority
Inventors:Nikolaos DimoudisGeorg FertigAlexander FidlerGuy GeorgesKlaus KaluzaMartin LanzendoerferCarola RiesStefan SeeberMarlene Thomas
A61P 37/00A61P 35/00A61P 35/04A61P 29/00A61P 19/10A61P 19/08C07K 2317/565C07K 2317/76C07K 2317/567C07K 2317/92C07K 2317/24C07K 2317/73C07K 2317/21C07K 16/2866C07K 2317/31C07K 2317/56C07K 2317/622A61K 2039/505C07K 16/28A61K 39/395
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Claims

exact text as granted — not AI-modified
1 . An isolated antibody binding to human CSF-1R, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain, and wherein the heavy chain variable domain comprises a CDR3 region comprising SEQ ID NO: 41, a CDR2 region comprising SEQ ID NO: 42, and a CDR1 region comprising SEQ ID NO: 43, and the light chain variable domain comprises a CDR3 region comprising SEQ ID NO: 44, a CDR2 region comprising SEQ ID NO: 45, and a CDR1 region comprising SEQ ID NO: 46. 
     
     
         2 . A pharmaceutical composition comprising the antibody according to  claim 1 . 
     
     
         3 . The pharmaceutical composition according to  claim 2 , wherein the antibody is formulated in a pharmaceutically acceptable carrier. 
     
     
         4 . The antibody according to  claim 1 , wherein the antibody is of human IgG1 subclass or is of human IgG4 subclass. 
     
     
         5 . The antibody according to  claim 1 , wherein the antibody is a chimeric, single chain, multispecific, or humanized antibody. 
     
     
         6 . A pharmaceutical composition comprising the antibody according to  claim 5 . 
     
     
         7 . The antibody according to  claim 1 , wherein the antibody is an antigen binding fragment. 
     
     
         8 . A pharmaceutical composition comprising the antibody according to  claim 7 . 
     
     
         9 . The antibody according to  claim 1 , wherein the antibody is a monoclonal antibody. 
     
     
         10 . A pharmaceutical composition comprising the antibody according to  claim 9 . 
     
     
         11 . An isolated antibody binding to human CSF-1R, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain, and wherein the heavy chain variable domain comprises SEQ ID NO: 47 and the light chain variable domain comprises SEQ ID NO: 48. 
     
     
         12 . A pharmaceutical composition comprising the antibody according to  claim 11 . 
     
     
         13 . The pharmaceutical composition according to  claim 12 , wherein the antibody is formulated in a pharmaceutically acceptable carrier. 
     
     
         14 . The antibody according to  claim 11 , wherein the antibody is of human IgG1 subclass or is of human IgG4 subclass. 
     
     
         15 . The antibody according to  claim 11 , wherein the antibody is a chimeric, single chain, multispecific, or humanized antibody. 
     
     
         16 . A pharmaceutical composition comprising the antibody according to  claim 15 . 
     
     
         17 . The antibody according to  claim 11 , wherein the antibody is an antigen binding fragment. 
     
     
         18 . A pharmaceutical composition comprising the antibody according to  claim 17 . 
     
     
         19 . The antibody according to  claim 11 , wherein the antibody is a monoclonal antibody. 
     
     
         20 . A pharmaceutical composition comprising the antibody according to  claim 19 .

Join the waitlist — get patent alerts

Track US2019300614A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.